A5034720013- Psoriasis: Treatment and Pathogenesis
- Dermatology and Skin Diseases
- Autoimmune Bullous Skin Diseases
- Health Systems, Economic Evaluations, Quality of Life
- Asthma and respiratory diseases
- Pharmaceutical studies and practices
- Spondyloarthritis Studies and Treatments
- Autoimmune and Inflammatory Disorders Research
- Rheumatoid Arthritis Research and Therapies
- Immunodeficiency and Autoimmune Disorders
- Nail Diseases and Treatments
- Cancer and Skin Lesions
- Cytokine Signaling Pathways and Interactions
- Skin Diseases and Diabetes
- Urticaria and Related Conditions
- Complementary and Alternative Medicine Studies
- Antifungal resistance and susceptibility
- Eosinophilic Disorders and Syndromes
- Pregnancy and Medication Impact
- Nonmelanoma Skin Cancer Studies
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Cutaneous lymphoproliferative disorders research
- Oral Health Pathology and Treatment
- Therapeutic Uses of Natural Elements
- Pharmacogenetics and Drug Metabolism
Hospital Universitario de La Princesa
2016-2025
Universidad Autónoma de Madrid
2001-2024
Helsinki University Hospital
2023
Technical University of Munich
2023
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
2023
Fundación Instituto Valenciano de Oncología
2023
Aristotle University of Thessaloniki
2023
Hospital Infantil Universitario Niño Jesús
2023
Hospital Universitario 12 De Octubre
2020
Hospital General Universitario de Alicante Doctor Balmis
2020
Patients with moderate to severe psoriasis are undertreated. To solve this persistent problem, the consensus programme was performed define goals for treatment of plaque systemic therapy and improve patient care. An expert meeting a collaborative Delphi procedure were carried out. Nineteen dermatologists from different European countries met face-to-face discussion defined items through four-round process. Severity graded into mild disease. Mild disease as body surface area (BSA) ≤10...
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by authors. Any queries (other than missing content) should be directed to corresponding author article.
The diagnosis of acute myocarditis typically requires either endomyocardial biopsy (which is invasive) or cardiovascular magnetic resonance imaging not universally available). Additional approaches to are desirable. We sought identify a novel microRNA for the myocarditis.To specific myocarditis, we performed microarray analyses and quantitative polymerase-chain-reaction (qPCR) assays in sorted CD4+ T cells type 17 helper (Th17) after inducing experimental autoimmune myocardial infarction...
Tuberculosis has a major global impact. Immunocompetent hosts usually control this disease, resulting in an asymptomatic latent tuberculosis infection (LTBI). Because TNF inhibitors increase the risk of reactivation, current guidelines recommend screening before starting any biologic drug, and chemoprophylaxis if LTBI is diagnosed. Available evidence from clinical trials real-world studies suggests that IL-17 IL-23 do not reactivation. To evaluate psoriasis patients with treated or untreated...
To investigate the presence of synovitis, tenosynovitis and enthesitis with power Doppler (PD) ultrasonography (US) in patients psoriasis without musculoskeletal diseases as compared controls other skin disorders.A total 162 plaque 60 age-matched diseases, all were prospectively recruited at 14 centres. They underwent dermatological rheumatological assessment a blinded PDUS evaluation. Clinical included demographics, comorbidities, severity psoriasis, work sport activities clinical...
<h3>Objective</h3>To describe the use of systemic therapy for psoriasis (biologic and nonbiologic [classic] drugs) in patients not adequately represented randomized controlled trials (RCTs) risk serious adverse events (SAEs) these patients.<h3>Design</h3>A registry inception cohort was used.<h3>Setting</h3>Thirteen dermatology departments Spain participated.<h3>Patients</h3>A consecutive sample treated with biologics a systematic classic were evaluated. A total 1042 (2179 person-years)...
Estimates of psoriatic arthritis (PsA) prevalence among psoriasis patients vary widely (5-40%). The time to development PsA in with plaque also remains unclear.To examine whether length since diagnosis affects risk developing PsA, and assess differences quality life (QoL), work-related issues, comorbidities healthcare resource utilization (HCRU) for vs. psoriasis.This large cross-sectional observational study was conducted the UK, Italy, France, Spain Germany 2006. Dermatologists who...
Targeting miR-21 may be a new way to treat psoriasis.
Abstract Background The relationship between psoriasis and associated diseases has drawn particular interest in recent years. To provide appropriate management of from an early stage, it is necessary to include prompt diagnosis concomitant disease prevent treat any comorbidity found. Such integrated approach also serves ensure that the drugs used do not interfere with psoriasis, vice versa. Objective dermatologist a guide focuses specifically on most often found patients psoriasis. Methods...
An update of the European S3-Guidelines on systemic treatment psoriasis vulgaris – Dermatology Forum (EDF) in cooperation with Academy and Venereology (EADV) International Psoriasis Council (IPC was published December 2015.1, 2 In addition to interventions discussed update, Committee for Medicinal Products Human Use (CHMP) Medicines Agency (EMA) approved apremilast secukinumab as new options psoriasis. The Commission granted a marketing authorization both treatments 15 January 2015.3, 4...
Abstract Psoriasis is a highly prevalent disease with major impact on quality of life; therefore, appropriate patient management mandatory. Given that many issues in psoriasis are controversial and not clearly defined by evidence‐based medicine, very variable. Expert consensus can generate practical guidelines for optimization care. Much has changed since 2009, when the Consensus Document Evaluation Treatment Moderate to Severe was published Spanish Group ( GEP ) Academy Dermatology...
Abstract Background Few reported studies compare drug survival in moderate‐to‐severe psoriasis vulgaris. Objectives To describe and of systemic drugs, including biologic agents (infliximab, etanercept, adalimumab ustekinumab) classical drugs (acitretin, ciclosporin methotrexate) psoriasis. Methods This was a multicenter, prospective, cohort study patients receiving therapies between 2008 2013 12 hospitals Spain. Baseline data discontinuation were collected. Drug is presented using...
To assess patient-reported outcomes (PRO) in patients with moderate-to-severe plaque psoriasis receiving continuous or paused etanercept treatment.In a multicentre European open-label study, one group (n = 352) received therapy: 25 mg subcutaneously (SC) twice weekly (BIW) throughout 54-weeks. The other 359) 50 SC BIW (<or= 12 weeks) until response was adequate by Physician Global Assessment; after returned, retreatment (25 BIW) begun. PRO included the Dermatology Life Quality Index (DLQI),...
Journal Article Safety and effectiveness of ustekinumab antitumour necrosis factor therapy in patients with psoriasis chronic viral hepatitis B or C: a retrospective, multicentre study clinical setting Get access R. Navarro, Navarro Department Dermatology, Hospital Universitario de la Princesa, Madrid, Spain Raquel Navarro. E‐mail: nat_eraa@hotmail.com Search for other works by this author on: Oxford Academic Google Scholar E. Vilarrasa, Vilarrasa Santa Creu i Sant Pau, Universitat Autónoma...